AKTX (STOCKS)
Akari Therapeutics plc ADR (0.01 USD)
$4.247500
+0.417500 (+10.90%)
Prev close: $3.830000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Abizer Gaslightwala
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $189.67M
- Employees
- 12
- P/E (TTM)
- -0.01
- P/B (TTM)
- 6.12
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.00 | $-1.53 | +1.5300 | +100.00% |
|
Sep 2025 (Q3)
|
$0.00 | $-3.13 | +3.1281 | +100.00% |
|
Jun 2025 (Q2)
|
$0.00 | $-4.69 | +4.6920 | +100.00% |
|
Mar 2021 (Q1)
|
$0.00 | $0.00 | +0.0000 | +0.00% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | -$1.03M |
| Operating Expenses | $17.28M |
| Selling, General, and Administrative Expenses | $9.28M |
| Research and Development | $2.82M |
| Other Operating Expenses | $5.18M |
| Operating Income/Loss | -$17.28M |
| Income/Loss From Continuing Operations After Tax | -$18.30M |
| Income/Loss From Continuing Operations Before Tax | -$18.30M |
| Interest Expense, Operating | $100.00K |
| Net Income/Loss | -$17.30M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$17.30M |
| Net Income/Loss Available To Common Stockholders, Basic | -$17.30M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.00 |
| Diluted Earnings Per Share | $0.00 |
| Basic Average Shares | 67,328,128,638 |
| Diluted Average Shares | 67,328,128,638 |
| Assets | $47.89M |
| Current Assets | $5.46M |
| Prepaid Expenses | $185.00K |
| Other Current Assets | $5.28M |
| Noncurrent Assets | $42.43M |
| Liabilities | $19.56M |
| Current Liabilities | $12.35M |
| Accounts Payable | $8.77M |
| Other Current Liabilities | $3.58M |
| Noncurrent Liabilities | $7.21M |
| Equity | $28.33M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $28.33M |
| Liabilities And Equity | $47.89M |
| Net Cash Flow From Operating Activities | -$10.57M |
| Net Cash Flow From Operating Activities, Continuing | -$10.57M |
| Net Cash Flow From Investing Activities | -$2.60M |
| Net Cash Flow From Investing Activities, Continuing | -$2.60M |
| Net Cash Flow From Financing Activities | $13.17M |
| Net Cash Flow From Financing Activities, Continuing | $13.17M |
| Exchange Gains/Losses | $1.00K |
| Net Cash Flow | -$1.00K |
| Net Cash Flow, Continuing | -$2.00K |
| Comprehensive Income/Loss | -$17.34M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$17.34M |
| Other Comprehensive Income/Loss | -$17.34M |
| Other Comprehensive Income/Loss Attributable To Parent | -$44.00K |